HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies

By sjmartinez • March 15, 2024

Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, Baeten JM, Liu A, Hoover KW, Celum C, Grinsztejn B, Morris S, Wheeler DP, Mayer KH, Golub SA, Bekker LG, Diabaté S, Hoornenborg E, Myers J, Leech AA, McCormack S, Chan PA, Sweat M, Matthews LT, Grant R; Global F/TDF PrEP Study Team. HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clin Infect Dis. 2024 Mar 14:ciae143. doi: 10.1093/cid/ciae143. Epub ahead of print. PMID: 38484128.

Tags: emtricitabine, Hematology/Oncology, HIV-1, Pre-exposure prophylaxis, Publications, tenofovir disoproxil fumarate

Related Posts

The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer

Cecchini M, Han SW, Lee S, Lee KW, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao[...]

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]

Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

Chen X, Mao Z, Kolawole EM, Persechino M, Jude KM, Ogishi M, Mo KC, McLaughlin J, Cheng D, Xiang X, Yang X, Gee C, Liu[...]